ObjectiveObjective to investigate the effect of Sacubitril/trivalsartan on left ventricular remodeling and cardiac function in patients with acute anterior myocardial infarction after emergency percutaneous coronary intervention(PCI).

MethodsSixty inpatients with acute anterior myocardial infarction of Hefei Second People's Hospital from January 2019 to December 2019 were selected as the research objects.The patients were randomly divided into experimental group(n=30) and control group(n=30).Both groups were treated with emergency PCI.Besides the conventional treatment, for 12 months, Sacubitril/trivalsartan and benazepril were given to the patients in experimental and control group respectively.The follow-up was done at the day before discharge and at 1, 3, 6 and 12 months after discharge.Left ventricular end diastolic diameter(LVEDD), left ventricular ejection fraction(LVEF), interventricular septal thickness(IVST) and left ventricular mass index(LVMI) were recorded.At the same time, NT-proBNP, KCCQ, 6MWT, cardiovascular adverse events and adverse drug reactions were recorded.

ResultsLVEDD in the observation group was lower than that in the control group at 1, 3, 6, 12 months after discharge(P < 0.05 to P < 0.01);LVEF in the observation group increased 1, 3, 6 and 12 months after discharge compared with the day before discharge(P < 0.05), LVEF in the control group increased 6 and 12 months after discharge compared with the day before discharge(P < 0.05), LVMI in the observation group decreased 3, 6 and 12 months after discharge compared with the control group(P < 0.05).With the prolongation of treatment time, NT proBNP of patients in the two groups decreased gradually(P < 0.05), and the observation group decreased significantly at 1 and 3 months after discharge when compared with the control group (P < 0.05 and P < 0.01);KCCQ of patients in the two groups increased at 3, 6, 12 months after discharge compared with the day before discharge(P < 0.05), and 6MWT of patients in the two groups increased significantly at 1, 3, 6, 12 months after discharge compared with the day before discharge(P < 0.05).There was no significant difference between the two groups in the total incidence of major cardiovascular and cerebrovascular adverse events and adverse drug reactions(P>0.05).

ConclusionsSacubitril/trivalsartan can improve the cardiac function of patients with acute anterior myocardial infarction as effective and safe as benazepril, even better in patients with left ventricular remodeling and cardiac function improvement speed.